| Literature DB >> 28965098 |
Naeemah Abrahams1, Soraya Seedat2, Carl Lombard3, Andre P Kengne4, Bronwyn Myers5, Alesha Sewnath1, Shibe Mhlongo1, Gita Ramjee6, Nasheeta Peer7, Claudia Garcia-Moreno8, Rachel Jewkes1.
Abstract
INTRODUCTION: South Africa is a country known for its high levels of HIV infection and sexual violence. Although the interface between gender-based violence, HIV and mental health has been described, there are substantial gaps in knowledge of the medium-term and long-term health impact. The 2010 Global Burden of Disease study excluded many health outcomes associated with rape and other forms of gender-based violence because systematic reviews revealed huge gaps in data and poor evidence of health effects. This study aims to describe the incidence and attributable burden of physical and mental health problems (including HIV acquisition) in adult women over a 2-year postrape period, through comparison with a cohort of women who have not been raped. The study will substantially advance our understanding of the impact of rape and will generate robust data to assist in the development of postrape health services and the delivery of evidence-based care. METHODS AND ANALYSIS: This longitudinal study seeks to recruit 1008 rape-exposed and 1008 rape non-exposed women. Women were recruited from health services, and assessments were carried out at baseline, 3, 6, 9, 12, 18 and 24 months. Outcome measures include exposure to risk factors; mental health status; cardio-metabolic risks; and biomarkers for HIV, sexually transmitted infections, pregnancy and stress. The primary analysis will be to compare HIV incidence in the two groups using log-rank tests. Appropriate models to predict health outcomes over time will also be applied. ETHICS AND DISSEMINATION: The South African Medical Research Council's Ethics Committee approved the study. As rape is a key element of the study, the safety and protection of participants guides the research process. We will adopt a research uptake strategy to ensure dissemination to policy makers, service providers and advocacy groups. Peer-reviewed journal articles will be published. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: HIV; health impact; rape
Mesh:
Year: 2017 PMID: 28965098 PMCID: PMC5640088 DOI: 10.1136/bmjopen-2017-017296
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Rape Impact Cohort Evaluation study flow chart of participants and samples.
Exposure and outcome measures at each data collection time point
| Variable group | Measures | Source of measures | |
| A | IPV exposure | Ever physical, sexual, emotional | WHO multi-country study instrument |
| B | Rape circumstances and physical trauma/injuries | Rape circumstances: number of perpetrators, relationship to perpetrator, weapon use, degree of violence, type of rape | Jewkes |
| C | Rape stigma and social support | Rape stigma and self-blame | Social Support Appraisal Scale |
| D | Demographic factors | Demographic factors: age, income, education, employment, relationship status, sexual orientation | Jewkes |
| E | Mental health outcomes | Depression | MINI for psychosis and anxiety disorders |
| F | Other trauma | Previous trauma: child abuse, other interpersonal violence or traumatic life events | Childhood trauma scale Bernstein |
| G | Criminal justice processes and circumstances of the rape | Case progression: case dropped, arrest, bail, guilty plea, case withdrawn, trial commenced, testimony in court given, trial outcome | Jewkes |
| H | Acquiescence to male domination of sex | Attitudes to gender relations and perceived social norms | Jewkes |
| I | Own sexual risk behaviour | Transactional sex | Jewkes |
| J | Partner riskiness | STIs of current partner | Jewkes |
| K | Biological risk enhancers or co-factors | Hormonal contraception use at baseline and ongoing | Questions from the Demographic and Health Survey |
| L | Cardio-metabolic risk assessment | Screening questions for risk assessment | Questions from the WHO STEPs questionnaire |
| M | Healthcare seeking practices postrape health, HIV testing and adherence | Completion of PEP and STI treatment | Items developed and tested in pilot |
| O | Reproductive and child health | Contraception, fertility, pregnancies, reproductive health | Questions developed and adapted from Demographic and Health Survey |
ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; BP, blood pressure; CES-D, Center for Epidemiologic Studies Depression Scale; CRP, C-reactive protein; DUDIT, Drug Use Disorders Identification Test; IPV, intimate partner violence; MINI, Mini International Neuropsychiatric Interview; PEP, postexposure prophylaxis; PTSD, post-traumatic stress disorder; RICE, Rape Impact Cohort Evaluation; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; STI, sexually transmitted infection.
Clinical assessments and biological samples at each visit
| Baseline | 3 months | 6 months | 9 months | 12 months | 18 months | 24 months | |
| Biometrics | X | X | X | X | X | X | X |
| Clinical assessment | X | X | X | X | X | X | X |
| Mental health assessment | X | X | X | X | X | X | X |
| HIV and trauma counselling | X | X | X | X | X | X | X |
| Laboratory evaluations | |||||||
| HIV rapid test and ELISA | X | X | X | X | X | X | X |
| Pregnancy test | X | X | X | X | X | X | X |
| Trichomonas swab | X | X | X | X | X | X | X |
| HSV2 | X | X | X | X | X | X | X |
| Glucose/lipid panels CRP ultrasensitive (cardiac), Gamma-GT, ALT (SGPT), AST (SGOT), creatinine | X | X | X | ||||
| Cortisol (hair sample) | X | X | X | X | X | ||
| Genetic and epigenetic tests | X | X | X | X | X | X | X |
| Virology (HIV positive) | |||||||
| Viral load and CD4 | X | X | X | X | |||
| p-Antigen 24 (sero-converted) | X | X | X | X | X | X | X |
| Storage | |||||||
| Plasma | X | X | X | X | X | X | X |
| Serum | X | X | X | X | X | X | X |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HSV2, herpes simplex virus type 2; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.